Drug
Ado-Trastuzumab Emtansine clinical trials
Also written Trastuzumab emtansine, T-DM1, Kadcyla and Trastuzumab-MCC-DM1.
- studies test it
- 87
- open now
- 15
- in phase 3
- 16
- first study started
- 2006
Keep track of what changes. Save the Ado-Trastuzumab Emtansine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
87 studies that test it; most in 2014 (12)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 12 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 21
- Phase 2
- 54
- Phase 3
- 16
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 54
Hoffmann-La Roche (21) · Dana-Farber Cancer Institute (9) · Genentech, Inc. (7) · Jules Bordet Institute (4) · National Cancer Institute (NCI) (2) · Jenny C. Chang, MD (2) · OHSU Knight Cancer Institute (2) · Fondazione del Piemonte per l'Oncologia (2)
Often tested with
Tested in the same studies.
Trastuzumab (20) · Pertuzumab (17) · Paclitaxel (12) · Atezolizumab (9) · Ipatasertib (6) · Palbociclib (6) · Alectinib (6) · Tucatinib (6)
Studies
Open first, then newest update. How each study uses Ado-Trastuzumab Emtansine is read from its arms, and is right about nine times in ten.
Testing it · 87
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingPhase 2NRG OncologyNCT05408845Written as Trastuzumab Emtansine
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Trastuzumab emtansine (T-DM1)
- ATEMPT 2.0: Adjuvant T-DM1 vs THRecruitingPhase 2Dana-Farber Cancer InstituteNCT04893109Written as trastuzumab-emtansine
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Written as T-DM1
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05673928Written as Trastuzumab emtansine
- A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingPhase 3GeneQuantum Healthcare (Suzhou) Co., Ltd.NCT07673029Written as T-DM1
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as T-DM1 and Pertuzumab
- Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasRecruitingPhase 2Dana-Farber Cancer InstituteNCT04620187Written as Ado-trastuzumab (T) emtansine (T-DM1)
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352Written as Trastuzumab emtansine
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Trastuzumab emtansine
- Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerRecruitingPhase 2/3University of VirginiaNCT05288777Written as T-DM1
- Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionRecruitingPhase 2Population Health Research InstituteNCT04680442Written as Trastuzumab emtansine
- Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP TherapyRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06125834Written as Trastuzumab Emtansine (T-DM1)
- Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast CancerRecruitingNot applicableN.N. Petrov National Medical Research Center of OncologyNCT06299852Written as Trastuzumab emtansine
- Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)Not yet recruitingPhase 2David Garcia CincaNCT04301375Written as TDM1
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Trastuzumab Emtansine
- T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02326974Written as T-DM1
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342Written as Trastuzumab Emtansine
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02675829Written as ado-trastuzumab emtansine
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Trastuzumab emtansine
See all 87 studies that test Ado-Trastuzumab Emtansine →
Given in every arm · 29 — Ado-Trastuzumab Emtansine is usual care beside what is tested
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as Trastuzumab emtansine
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingPhase 3SWOG Cancer Research NetworkNCT07578116Written as Trastuzumab Emtansine
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingPhase 2University of ChicagoNCT06348134Written as Trastuzumab emtansine
- Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyNot yet recruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT05560308Written as Trastuzumab Emtansine for Injection
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT04266249Written as Trastuzumab Emtansine
- A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingPhase 1/2Ascendis Pharma Oncology Division A/SNCT05081609Written as Trastuzumab emtansine (T-DM1)
- Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast CancerCompletedPhase 1Nancy Lin, MDNCT02390427Written as Trastuzumab emtansine
- A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive, not recruitingPhase 3Hoffmann-La RocheNCT04873362Written as Trastuzumab Emtansine
- A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT03975647Written as T-DM1
- T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04457596Written as Trastuzumab Emtansine
- A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)TerminatedPhase 3Hoffmann-La RocheNCT04740918Written as Trastuzumab Emtansine
- ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerActive, not recruitingPhase 1Enliven TherapeuticsNCT05650879Written as Trastuzumab emtansine
- A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerCompletedPhase 3Hoffmann-La RocheNCT03726879Written as Trastuzumab Emtansine
- T-DM1 and Palbociclib for Metastatic HER2 Breast CancerCompletedPhase 2University of ArizonaNCT03530696Written as T-DM1
- Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerTerminatedPhase 1/2University of Kansas Medical CenterNCT03709082Written as T-DM1
- TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryStatus unknownPhase 2Academic and Community Cancer Research UnitedNCT04197687Written as Trastuzumab Emtansine
- T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic RadiosurgeryTerminatedPhase 1/2National Cancer Institute (NCI)NCT03190967Written as T-DM1
- T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast CancerWithdrawnPhase 2Academic and Community Cancer Research UnitedNCT04351230Written as Trastuzumab Emtansine
- Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerActive, not recruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT04398914Written as T-DM1
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedPhase 1National Cancer Institute (NCI)NCT04296942Written as Ado-trastuzumab emtansine
Showing 20 of 29.
As the comparator · 10 — what is tested is compared with Ado-Trastuzumab Emtansine
- A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapyRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06830889Written as T-DM1
- Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07008976Written as Trastuzumab Emtansine for Injection
- JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerRecruitingPhase 3Shanghai JMT-Bio Inc.NCT06846437Written as Trastuzumab emtansine (T-DM1)
- DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast CancerRecruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06313086Written as trastuzumab emtansine
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]CompletedPhase 3Daiichi SankyoNCT03529110Written as Ado-trastuzumab emtansine (T-DM1)
- A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT06126640Written as Trastuzumab Emtansine
- A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active, not recruitingPhase 3Daiichi SankyoNCT04622319Written as T-DM1
- A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyActive, not recruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT06968585Written as T-DM1
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerCompletedPhase 3Hoffmann-La RocheNCT05415215Written as Trastuzumab Emtansine
- A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast CancerStatus unknownPhase 2/3Shanghai Miracogen Inc.NCT04924699Written as Trastuzumab Emtansine for Injection
Codes
What other systems call Ado-Trastuzumab Emtansine · ClinicalTrials.gg INT006841
- MeSH (NLM) D000080044Ado-Trastuzumab EmtansineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) SE2KH7T06FTRASTUZUMAB EMTANSINEConfirmed FDA, NLM, Wikidata
- RxNorm 1371041Confirmed FDA, Wikidata
- Wikidata Q3997863ado-trastuzumab emtansineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82492Trastuzumab EmtansineOne source FDA
- DrugBank DB05773One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000080044 | Ado-Trastuzumab Emtansine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | SE2KH7T06F | TRASTUZUMAB EMTANSINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1371041 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3997863 | ado-trastuzumab emtansine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82492 | Trastuzumab Emtansine | One source FDA |
| DrugBank | DB05773 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.